Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EMBCNASDAQ:IRMDNASDAQ:LUCDNASDAQ:RXST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBCEmbecta$10.61+1.5%$11.85$10.20▼$21.48$620.08M1.24468,711 shs593,756 shsIRMDIradimed$59.79+3.5%$52.50$41.69▼$63.29$760.23M0.9143,251 shs51,455 shsLUCDLucid Diagnostics$1.26+1.2%$1.35$0.68▼$1.80$136.32M1.28556,801 shs917,517 shsRXSTRxSight$15.81+1.8%$16.03$12.53▼$60.81$642.47M1.32698,043 shs974,313 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBCEmbecta-1.60%-2.52%-17.91%-17.06%-15.52%IRMDIradimed-0.53%+13.11%+8.08%+8.55%+36.07%LUCDLucid Diagnostics-10.75%-21.70%-3.11%-4.23%+39.81%RXSTRxSight+3.19%-0.96%-2.02%-42.18%-73.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBCEmbecta4.8539 of 5 stars3.25.03.30.02.63.33.8IRMDIradimed4.7808 of 5 stars2.53.02.54.44.03.31.9LUCDLucid Diagnostics2.5466 of 5 stars3.63.00.00.02.01.70.6RXSTRxSight2.9938 of 5 stars4.21.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBCEmbecta 2.33Hold$19.3382.22% UpsideIRMDIradimed 3.00Buy$72.0020.42% UpsideLUCDLucid Diagnostics 3.20Buy$3.50177.78% UpsideRXSTRxSight 2.30Hold$37.90139.72% UpsideCurrent Analyst Ratings BreakdownLatest LUCD, IRMD, RXST, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.005/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.004/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBCEmbecta$1.08B0.57$2.46 per share4.32($13.23) per share-0.80IRMDIradimed$75.15M10.12$1.49 per share40.12$5.66 per share10.56LUCDLucid Diagnostics$4.17M32.67N/AN/A($0.47) per share-2.68RXSTRxSight$148.31M4.33N/AN/A$4.47 per share3.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBCEmbecta$78.30M$0.9010.613.460.785.25%-19.22%11.92%8/8/2025 (Estimated)IRMDIradimed$19.23M$1.5539.8629.90N/A26.26%24.12%21.20%7/30/2025 (Estimated)LUCDLucid Diagnostics-$52.67M-$1.34N/AN/AN/A-1,069.87%N/A-123.54%8/11/2025 (Estimated)RXSTRxSight-$48.61M-$0.67N/AN/AN/A-23.92%-14.00%-12.51%8/4/2025 (Estimated)Latest LUCD, IRMD, RXST, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBCEmbecta$0.605.66%N/A66.67%N/AIRMDIradimed$0.681.14%N/A43.87%1 YearsLUCDLucid DiagnosticsN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ALatest LUCD, IRMD, RXST, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20255/5/2025IRMDIradimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBCEmbectaN/A2.241.67IRMDIradimedN/A9.217.82LUCDLucid DiagnosticsN/A1.181.14RXSTRxSightN/A12.6711.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBCEmbecta93.83%IRMDIradimed92.34%LUCDLucid Diagnostics74.01%RXSTRxSight78.78%Insider OwnershipCompanyInsider OwnershipEMBCEmbecta0.42%IRMDIradimed36.80%LUCDLucid Diagnostics6.80%RXSTRxSight9.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMBCEmbecta1,90058.44 million57.89 millionOptionableIRMDIradimed11012.72 million7.97 millionOptionableLUCDLucid Diagnostics70108.19 million54.12 millionNo DataRXSTRxSight22040.64 million36.53 millionOptionableLUCD, IRMD, RXST, and EMBC HeadlinesRecent News About These CompaniesRxSight (NASDAQ:RXST) Stock Price Down 5.5% - What's Next?May 31 at 2:09 PM | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by Nuveen Asset Management LLCMay 31 at 3:37 AM | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by Two Sigma Investments LPMay 29, 2025 | marketbeat.comPolar Asset Management Partners Inc. Buys Shares of 46,700 RxSight, Inc. (NASDAQ:RXST)May 28, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by D. E. Shaw & Co. Inc.May 28, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 74,800 Shares of RxSight, Inc. (NASDAQ:RXST)May 27, 2025 | marketbeat.comRoyal Bank of Canada Raises Holdings in RxSight, Inc. (NASDAQ:RXST)May 27, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Acquired by Voloridge Investment Management LLCMay 26, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Stock Price Down 4.7% - What's Next?May 25, 2025 | marketbeat.comTwinbeech Capital LP Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 25, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Receives $37.90 Average PT from AnalystsMay 24, 2025 | americanbankingnews.comDo Options Traders Know Something About RxSight Stock We Don't?May 23, 2025 | msn.comRxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Hold" by BrokeragesMay 23, 2025 | marketbeat.comSilvercrest Asset Management Group LLC Invests $2.99 Million in RxSight, Inc. (NASDAQ:RXST)May 22, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Upgraded to Overweight at Wells Fargo & CompanyMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 21, 2025 | marketbeat.com5RXST : Deep Dive Into RxSight Stock: Analyst Perspectives (13 Ratings)May 20, 2025 | benzinga.comRxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology ForumMay 20, 2025 | globenewswire.comPolar Asset Management Partners Inc. Makes New Investment in RxSight, Inc. (NASDAQ:RXST)May 19, 2025 | marketbeat.comPolar Capital Holdings Plc Purchases 39,347 Shares of RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUCD, IRMD, RXST, and EMBC Company DescriptionsEmbecta NASDAQ:EMBC$10.61 +0.16 (+1.53%) Closing price 04:00 PM EasternExtended Trading$10.61 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Iradimed NASDAQ:IRMD$59.79 +2.00 (+3.46%) Closing price 04:00 PM EasternExtended Trading$59.68 -0.10 (-0.18%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Lucid Diagnostics NASDAQ:LUCD$1.26 +0.02 (+1.20%) Closing price 04:00 PM EasternExtended Trading$1.27 +0.01 (+0.87%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.RxSight NASDAQ:RXST$15.81 +0.28 (+1.80%) Closing price 04:00 PM EasternExtended Trading$15.76 -0.05 (-0.34%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
